Compare · HRMY vs NVO
HRMY vs NVO
Side-by-side comparison of Harmony Biosciences Holdings Inc. (HRMY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HRMY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $203.51B, about 111.3x HRMY ($1.83B).
- Over the past year, HRMY is down 11.1% and NVO is down 37.4% - HRMY leads by 26.3 points.
- HRMY has been more active in the news (12 items in the past 4 weeks vs 10 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 23 for HRMY).
- Company
- Harmony Biosciences Holdings Inc.
- Novo Nordisk A/S
- Price
- $31.61+0.40%
- $45.60+0.22%
- Market cap
- $1.83B
- $203.51B
- 1M return
- +1.89%
- +13.21%
- 1Y return
- -11.07%
- -37.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 10
- Recent ratings
- 23
- 25
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HRMY
- Harmony Biosciences to Participate in Upcoming Investor Conferences
- SEC Form 4 filed by Director Germano Geno J
- SEC Form 3 filed by new insider Germano Geno J
- SEC Form 4 filed by Director Szyper Linda M
- SEC Form 4 filed by Director Philip Ron M
- SEC Form 4 filed by Director Graf R. Mark
- SEC Form 4 filed by Director Sabater Juan A.
- SEC Form 4 filed by Director Sender Gary
- CHIEF MEDICAL OFFICER Budur Kumar converted options into 18,750 shares and covered exercise/tax liability with 8,882 shares, increasing direct ownership by 69% to 24,115 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Reicin Glenn
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
- The Next Generation of the GLP-1 Revolution Is Already Underway